Transforming growth factor-beta in breast cancer: too much, too late

The contribution of transforming growth factor (TGF)beta to breast cancer has been studied from a myriad perspectives since seminal studies more than two decades ago. Although the action of TGFbeta as a canonical tumor suppressor in breast is without a doubt, there is compelling evidence that TGFbet...

Full description

Saved in:
Bibliographic Details
Published inBreast cancer research : BCR Vol. 11; no. 1; p. 202
Main Authors Barcellos-Hoff, Mary Helen, Akhurst, Rosemary J
Format Journal Article
LanguageEnglish
Published England National Library of Medicine - MEDLINE Abstracts 01.01.2009
BioMed Central Ltd
BioMed Central
Subjects
Animals
Humans
Neoplasms - metabolism
Review
Signal Transduction
Transforming Growth Factor beta - physiology
Online AccessGet full text

Cover

More Information
Summary:The contribution of transforming growth factor (TGF)beta to breast cancer has been studied from a myriad perspectives since seminal studies more than two decades ago. Although the action of TGFbeta as a canonical tumor suppressor in breast is without a doubt, there is compelling evidence that TGFbeta is frequently subverted in a malignant plexus that drives breast cancer. New knowledge that TGFbeta regulates the DNA damage response, which underlies cancer therapy, reveals another facet of TGFbeta biology that impedes cancer control. Too much TGFbeta, too late in cancer progression is the fundamental motivation for pharmaceutical inhibition.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1465-542X
1465-5411
1465-542X
DOI:10.1186/bcr2224